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ABSTRACT

ARTICLE HISTORY

We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion
17p (n ¼ 578) were randomized 1:1 to 420 mg daily ibrutinib or placebo plus 6 cycles of bendamustine plus rituximab (BR), followed by ibrutinib or placebo alone. Median follow-up was
63.7 months. Median investigator-assessed progression-free survival was longer with ibrutinib plus
BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229 [95% confidence interval (CI) 0.183–0.286]; p < .0001). Despite crossover of 63.3% of patients from the placebo plus BR
arm to ibrutinib treatment upon disease progression, ibrutinib plus BR versus placebo plus BR
demonstrated an overall survival benefit (HR 0.611 [95% CI 0.455–0.822]; p ¼ .0010; median not
reached in either arm). Long-term follow-up data confirm the survival benefit of ibrutinib plus BR
over BR alone. Safety profiles were consistent with those known for ibrutinib and BR.
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Introduction
Ibrutinib, administered orally once daily, is approved
to treat adults with various B-cell malignancies in the
United States, European Union, and other countries
[1–3]. This first-in-class covalent inhibitor of Bruton’s
tyrosine kinase (BTK) has changed the treatment landscape for patients with chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL) [4–7] and is
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one of the preferred treatments for patients with or
without deletion 17p/TP53 mutation, who have previously untreated or relapsed/refractory (R/R) disease [6].
Ibrutinib was evaluated as a single-agent treatment
in patients with R/R CLL/SLL in an open-label randomized, multicenter phase 3 trial (RESONATETM) [8–10]. In
the final analysis of the study (median follow-up,
65.3 months in the ibrutinib arm), patients who
received ibrutinib (n ¼ 195) versus ofatumumab
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Enrollment dates:
September 2012 to January 2014
Endpoints investigated in the
5-year final analysis:
investigator-assessed PFS,d
OS, and ORR, as well as safety

1:1b
Placebo plus BR (N=289)
BRc (≤6 cycles)
Oral placebo once daily
starting on Cycle 1, Day 2

Placebo
(treat to PD or
unacceptable
toxicity)

Crossover to ibrutinib
420 mg once daily
after PD permitted

Figure 1. Study design and follow-up assessments. IRC: independent review committee; PD: progressive disease. aDeletion 17p in
20% of examined cells. bStratified by purine analog refractory status (failure to respond or relapse in 12 months) and prior
lines of therapy (1 line versus >1 line). cSimilar dosing to Fischer et al. [13]; bendamustine: 70 mg/m2 intravenously on Days 2–3
in Cycle 1 and Days 1–2 in Cycles 2–6; rituximab: 375 mg/m2 on Day 1 of Cycle 1 and 500 mg/m2 on Day 1 of Cycles 2–6.
d
According to 2008 International Workshop on Chronic Lymphocytic Leukemia criteria (Hallek et al. [17]).

(n ¼ 196), including those with high-risk genomic features, had a superior progression-free survival (PFS;
hazard ratio [HR], 0.148; 95% confidence interval [CI]
0.113–0.196; p < .0001) [10]. Additionally, although
68% of patients in the ofatumumab arm crossed over
to the ibrutinib arm, an overall survival (OS) benefit
with ibrutinib was seen (HR 0.639; 95% CI 0.418–0.975;
censored for the crossover).
Before the availability of BTK inhibitors like ibrutinib,
which target the B-cell receptor signaling pathway, a
chemoimmunotherapy regimen of bendamustine (an
alkylating agent) plus rituximab (an anti-CD20 antibody)
was commonly used for patients with R/R CLL [11,12].
In a phase 2 study of 6 cycles of bendamustine plus
rituximab (BR) in patients with R/R CLL, overall response
rate (ORR) was 59% (complete response [CR], 9%),
median PFS was 15.2 months, and median OS was 33.9
months [13]. The HELIOS study was designed to determine whether ibrutinib therapy provided additional
benefit when combined with BR as a chemoimmunotherapy backbone. In a prior phase 1 b multicenter
study evaluating the safety and efficacy of continuous
ibrutinib plus 6 cycles of BR in 30 patients with R/R
CLL, the ORR was high (93.3%), with 70.3% of patients
remaining progression free at the 36-month landmark [14].
Here, we report outcomes of the final analysis of
HELIOS, a phase 3, randomized, double-blind, placebocontrolled study of ibrutinib plus 6 cycles of BR in
578 patients with R/R CLL/SLL (median follow-up,
63.7 months); findings from interim [15] and 3-year
analyses [16] were previously reported.

Patients and methods
The HELIOS study (NCT01611090) was conducted at
133 sites in 21 countries. The protocol was approved

by an independent ethics committee/institutional
review board at each site [15] and performed according to principles of the Declaration of Helsinki and
guidelines for Good Clinical Practice. Patients provided
informed consent before participation.

Patient eligibility
As previously described [15,16], eligible patients were
aged 18 years with active CLL/SLL disease meeting
the International Workshop on Chronic Lymphocytic
Leukemia 2008 criteria [17] for treatment. Included
patients also had R/R disease following 1 prior lines
of therapy (including 3% of patients in each arm who
received BR [15]); an Eastern Cooperative Oncology
Group performance status of 0–1; measurable lymph
node disease (>1.5 cm) by computed tomography (CT)
scan; and adequate liver and kidney function. Patients
with deletion 17p (20% of blood/bone marrow cells
examined by fluorescent in situ hybridization) were
excluded due to the known poor response to BR by
patients with this deletion. TP53 mutational testing
was not performed or included in the study’s exclusion criteria.

Study design
Patients were randomly assigned (1:1) to treatment
with ibrutinib (420 mg daily) plus BR (6 cycles of
bendamustine [70 mg/m2 intravenously on Days 2–3
of Cycle 1 and Days 1–2 of Cycles 2–6] and rituximab
[375 mg/m2 on Day 1 of Cycle 1 and 500 mg/m2 on
Day 1 of Cycles 2–6]) or placebo plus BR (Figure 1).
Patients then continued ibrutinib or placebo treatment
until unacceptable toxicity or confirmed disease
progression.
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Table 1. Patient disposition for the intent-to-treat population.
Median time on study, months (95% CI)
[Range]
Study treatment phase disposition, n (%)
Did not receive study drug
Discontinued study treatment
Primary reason for discontinuation,b n (%)
Investigator or sponsor decision (including end of follow-up on trial)c
Progressive disease or relapse
Adverse event
Withdrawal of consent
Death
Lost to follow-up
Crossover to ibrutinib

Ibrutinib plus BR (n ¼ 289)

Placebo plus BRa (n ¼ 289)

Total (N ¼ 578)

63.3 (62.1–64.4)
[0.2–73.5]

64.0 (63.0–64.8)
[0.1–74.5]

63.7 (62.8–64.3)
[0.1–74.5]

2 (0.7)
287 (99.3)

2 (0.7)
287 (99.3)

4 (0.7)
574 (99.3)

136
55
58
23
16
1

84
148
34
13
9
1
183

220
203
92
36
25
2

(47.1)
(19.0)
(20.1)
(8.0)
(5.5)
(0.3)
–

(29.1)
(51.2)
(11.8)
(4.5)
(3.1)
(0.3)
(66.3)

(38.1)
(35.1)
(15.9)
(6.2)
(4.3)
(0.3)
–

BR: bendamustine and rituximab; CI: confidence interval; TEAEs: treatment-emergent adverse events.
Following the prespecified interim analysis, placebo treatment was discontinued on 10 March 2015, as was the reporting of TEAEs for the placebo arm;
these patients had continued disease evaluation and follow-up and were permitted to cross over to ibrutinib after confirmed disease progression.
b
Includes patients who did not receive study medication.
c
Includes patients who rolled over to the phase 3b access study (CAN3001) or commercial ibrutinib.
a

Following the prespecified interim analysis (March
2015), the Data and Safety Monitoring Board recommended unblinding the study, therefore, placebo
treatment was discontinued for patients in the placebo plus BR arm. Treatment-emergent adverse event
(TEAE) reporting for this arm was also discontinued at
this time; these patients had continued disease evaluation and follow-up and were permitted to cross over
to ibrutinib after confirmed disease progression
(Figure 1). Safety data are reported for the ibrutinib
plus BR arm; adverse events (AEs) occurring in patients
who crossed over from the placebo plus BR arm to
ibrutinib arm are excluded.

Endpoints and follow-up assessments
Endpoints investigated in this final analysis included
investigator-assessed PFS, OS, ORR, and safety (Figure
1). PFS2 (time interval from randomization to either
progressive disease on next-line treatment, death, or
the start of subsequent antineoplastic therapy if progressive disease was not reported) was also
investigated.
Minimal residual disease (MRD) testing was first performed on the bone marrow at the time of a radiologically documented CR, and subsequently on
peripheral blood every 12 weeks [15,16]. Due to the
long half-life of anti-CD20 monoclonal antibodies such
as rituximab in peripheral blood, the first bone marrow sample was acquired to mitigate cross-reactivity
[15]. Testing was done at a central laboratory by flow
cytometry using an eight-color panel of antibodies in
line with the EuroFlow panel [15,16,18]. A protocol
amendment following the interim analysis enabled
MRD analysis for all patients with partial response (PR)
or better [16]. The patient proportion with

undetectable MRD increased through to the 3-year follow-up but plateaued thereafter, therefore data collection was terminated shortly afterwards.

Statistical analyses
All randomized patients were included in the efficacy
analysis (intent-to-treat population). Patients who
received 1 dose of the study drug were included in
the safety analysis (safety population).
In the interim analysis, overall concordance
between independent review committee (IRC)assessed and investigator-assessed progressive disease
was 90% and 85% in the ibrutinib plus BR and placebo plus BR arms, respectively [15]. PFS analyses
were performed using IRC assessments in the interim
analysis and investigator assessments in the long-term
analysis. For patients alive at the time of this analysis,
OS – defined as the time interval from randomization
to death, regardless of cause – was censored at the
last known date they were alive.
PFS distribution was estimated using the
Kaplan–Meier method and a stratified log-rank test.
Cox-proportional hazards model was used to calculate HR.

Results
Patient demographics and baseline characteristics
were well balanced between treatment arms and previously reported [15].

Treatment exposure and patient disposition
At the final analysis, median follow-up was
63.7 months (95% CI 62.8–64.3; range 0.1–74.5; Table
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Figure 2. Investigator-assessed PFS for ibrutinib plus BR versus placebo plus BR.

1) overall, and similar for patients in both treatment
arms. Median time on treatment in the ibrutinib plus
BR arm (n ¼ 287) was 55.7 months (range 0.2–72.9). As
placebo treatment was discontinued at the interim
analysis, median time on treatment in the placebo
plus
BR
arm
(n ¼ 287)
was
14.3 months
(range 0.2–30.6).
At the final analysis, 183 (63.3%) patients with confirmed disease progression crossed over from the placebo arm to single-agent ibrutinib treatment. The
most common reasons for treatment discontinuation
in the ibrutinib plus BR arm were investigator/sponsor
decision (136 of 289 patients [47.1%]; mainly consisting of patients reaching study end and rolling over to
an open-label access study, where ibrutinib was continued), AEs (58 patients [20.1%]; Table 1), and progressive disease/relapse (55 patients [19.0%]). In the
placebo plus BR arm, most common reasons for treatment discontinuation included progressive disease/
relapse (148 of 289 patients [51.2%]) and investigator/
sponsor decision (84 patients [29.1%]; mainly following
unblinding at the interim analysis).

Progression-free survival and overall survival
Median PFS for the ibrutinib plus BR arm at final analysis was 65.1 months (n ¼ 289); substantially longer
than for the placebo plus BR arm (median
14.3 months; n ¼ 289; HR 0.229 [95% CI 0.183–0.286];
p < .0001; Figure 2). The 60-month PFS rate was 52.7%

in the ibrutinib plus BR arm and 8.2% in the placebo
plus BR arm.
At the final 5-year analysis, the OS advantage for
patients in the ibrutinib plus BR arm versus placebo
plus BR arm was maintained despite crossover of 183
patients (63.3%) from the placebo plus BR arm to ibrutinib treatment (HR 0.611 [95% CI 0.455–0.822];
p ¼ .0010; Figure 3). Median OS was not reached in
either group; the 60-month OS rate was 75.7% for
ibrutinib plus BR versus 61.2% for placebo plus BR.
Median PFS2 was not reached in the ibrutinib plus
BR arm, notably longer than in the placebo plus BR
arm (63.0 months; HR 0.594 [95% CI 0.453–0.778];
p ¼ .0001). At the time of data cutoff, 52 (18.1%)
patients in the ibrutinib plus BR arm received at least
one subsequent antineoplastic therapy. Of the patients
in the placebo plus BR arm who did not receive ibrutinib as first subsequent therapy as part of crossover,
60 (20.9%) received other subsequent therapy. The
most commonly administered subsequent therapies in
the ibrutinib plus BR and placebo plus BR arms,
respectively, were monoclonal antibodies (7.7% and
12.2%; mainly rituximab), nitrogen mustard analogues
(7.7% and 10.8%; mainly cyclophosphamide), corticosteroids (4.2% and 10.1%), anthracyclines (1.4% and
6.6%; mainly doxorubicin), and other antineoplastic
agents (6.6% and 4.2%; including venetoclax: 4.5%
and 2.4%). In addition, 3 (1.0%) and 6 (2.1%) patients
in the ibrutinib plus BR and placebo plus BR arms
respectively, received allogenic stem cell transplant as
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Figure 3. Investigator-assessed OS for ibrutinib plus BR versus placebo plus BR.

subsequent therapy. Chemotherapy agents and antiCD20 antibodies were commonly administered
together in a variety of regimens, including R-CHOP
for treatment of Richter’s transformation. Of the 13
patients in the ibrutinib plus BR arm who received
subsequent venetoclax or venetoclax plus CD20 antibody treatment, 9 patients received it as first subsequent therapy to ibrutinib; best response was CR (3
subjects), PR (3 subjects), not reported (3 subjects).
For patients who received a subsequent antineoplastic therapy, the time from start of the first subsequent therapy to progression or death was longest
for patients who received ibrutinib subsequent to placebo plus BR (median not reached, 95% CI 45.57
months –not evaluable). For those who received subsequent therapy other than ibrutinib, the median time
from start of the first subsequent therapy to progression or death was similar for patients previously on
ibrutinib plus BR and those previously on placebo plus
BR (median (95% CI) 9.43 months (3.22  22.08), and
9.17 months (1.68  15.15), respectively).

Overall response rate
Investigator-assessed ORR was 87.2% for ibrutinib plus
BR versus 66.1% for placebo plus BR (p < .0001).
Responses deepened over time: CR/CR with incomplete bone marrow recovery rate (CRi) in the ibrutinib
arm increased from 21.5% (62/289) in the interim analysis to 38.1% (110/289) in the 3-year analysis and

40.8% (118/289) in the final analysis. The patient proportion with undetectable MRD in peripheral blood or
bone marrow in the final analysis was 28.7% in the
ibrutinib plus BR arm (similar to the 3-year analysis
[26.3%] [16], as MRD testing was ceased shortly after
the 3-year analysis).

Safety
TEAEs for the ibrutinib plus BR arm were consistent
with previous reports [15, 16]. Most patients (90.2%)
had at least 1 grade 3 TEAE and these occurred
most frequently in the first 6 months of treatment
(Table 2). Similar to the 3-year results, 69.0% of
patients had serious TEAEs (any grade) and 20.2% had
TEAEs leading to ibrutinib discontinuation (61.3% and
16.0%, respectively, in the 3-year analysis). During the
first 6 months in the ibrutinib plus BR arm, 7.7% of
patients discontinued ibrutinib due to AEs; this rate
decreased over time with continued single-agent ibrutinib treatment (Table 2).
The incidence of the TEAE of clinical interest, major
hemorrhage (any grade), was 5.6% in the ibrutinib
plus BR arm during the study duration, including 3
(1.0%) patients with grade 5 major hemorrhage (1
patient with a history of hypertension and an abdominal aortic aneurysm had an abdominal aortic aneurysm rupture, 1 patient had intraabdominal
hemorrhage following a fall, and 1 patient had postprocedural hemorrhage following colonoscopy and
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Table 2. Summary of prevalence of TEAEs over time (and overall) occurring in patients in the ibrutinib plus BR arm in the
final analysis.
Ibrutinib treatment duration
n (%)
Patients with any grade TEAEs
Patients with TEAEs of grade 3
Patients with any treatment-related TEAEa
Patients with any TESAE
Patients with any TEAE
leading to ibrutinib discontinuationb
Patients with any TEAEs
with a fatal outcomec

0–0.5 year
(n ¼ 287)
271 (94.4)
212 (73.9)
225 (78.4)
104 (36.2)
22 (7.7)

>0.5–1 year
(n ¼ 246)
216 (87.8)
111 (45.1)
145 (58.9)
47 (19.1)
15 (6.1)

>1–2 years
(n ¼ 216)
180 (83.3)
87 (40.3)
122 (56.5)
53 (24.5)
8 (3.7)

>2–3 years
(n ¼ 188)
141 (75.0)
62 (33.0)
76 (40.4)
40 (21.3)
3 (1.6)

>3–4 years
(n ¼ 171)
121 (70.8)
37 (21.6)
68 (39.8)
29 (17.0)
3 (1.8)

>4–5 years
(n ¼ 157)
114 (72.6)
35 (22.3)
50 (31.8)
29 (18.5)
2 (1.3)

>5–6 years
(n ¼ 129)
49 (38.0)
17 (13.2)
21 (16.3)
13 (10.1)
5 (3.9)

Overall
(n ¼ 287)
282 (98.3)
259 (90.2)
249 (86.8)
198 (69.0)
58 (20.2)

10 (3.5)

4 (1.6)

11 (5.1)

3 (1.6)

1 (0.6)

1 (0.6)

3 (2.3)

33 (11.5)

BR: bendamustine and rituximab; n: number of patients; TEAEs: treatment-emergent adverse events; TESAE: treatment-emergent serious adverse event.
Judged by the investigator to be very likely, probably, possibly, or definitely related to the study drug.
b
Patients who had TEAEs leading to discontinuation of ibrutinib were counted only at the interval when they discontinued ibrutinib.
c
Patients who had TEAE leading to death were counted only at the interval when they died.
a

colon adenoma excision; none received anticoagulants). Additionally, any grade TEAE incidences of
infections, neutropenia, diarrhea, anemia, hypertension, and atrial fibrillation, respectively, were 78.7%,
59.9%, 40.4%, 25.8%, 16.7%, and 11.8% in the ibrutinib
plus BR arm. Two (0.7%) patients in the ibrutinib plus
BR arm had grade 3 Aspergillus infections (onset of
events within the first and third year of treatment
with ibrutinib), 1 (0.3%) patient experienced a grade 2
cryptococcal infection (onset of event 7 months after
starting ibrutinib treatment), and 2 (0.7%) patients had
Pneumocystis infections (1 grade 3; 1 grade 5; onset of
both events within the second year of treatment
with ibrutinib).
From the interim to final analysis, the prevalence of
TEAEs generally decreased over time (Figure 4).
Infections and infestations rates and other AEs
declined over time. Ventricular tachyarrhythmia rates
(3 patients; 1.0%), based on a Standardised MedDRA
Queries narrow search, were unchanged from the
interim analysis in the ibrutinib plus BR arm. In the
final analysis, 3 (1.0%) patients had cerebrovascular
accidents (2 grade 2; 1 grade 3). In the ibrutinib plus
BR arm, 5 (1.7%) patients had Richter’s transformation
(4 cases of large cell lymphoma and 1 case with
‘other’ histology). At the interim analysis, there were
no transformations in the ibrutinib group and 3 in the
placebo group. Overall, 74 (25.8%) patients in the ibrutinib plus BR arm died: 35 due to AEs, 11 of which
were related to study treatment (5 cases of infection,
2 cases of second malignancy [chronic myelomonocytic leukemia and myelodysplastic syndrome], and 1
case each of the following: multi-organ failure, systemic inflammatory response syndrome, lung infiltration, aortic aneurysm rupture), 17 due to progressive
disease, and 22 due to other reasons (i.e. >30 days

after the last dose and not due to TEAEs/progressive disease).

Discussion
In this final analysis of the HELIOS trial, median PFS
for patients with R/R CLL/SLL who received a median
of 2.0 prior lines of therapy (range 1–11) in the ibrutinib plus BR arm was 5.4 years. In this patient population, HELIOS is the first study showing an OS benefit
with ibrutinib added to chemoimmunotherapy versus
chemoimmunotherapy alone [15].
At the time of the interim analysis (median followup, 17 months), ibrutinib plus BR significantly
improved PFS versus placebo plus BR for R/R CLL/SLL
[15]; IRC-assessed median PFS was not reached in the
ibrutinib plus BR arm versus 13.3 months in the placebo plus BR arm (HR 0.203 [95% CI 0.150–0.276];
p < .0001). This final analysis confirms the persistent
benefit of ibrutinib plus chemoimmunotherapy;
median investigator-assessed PFS for the ibrutinib plus
BR arm was substantially longer than the placebo plus
BR arm (HR 0.229 [95% CI 0.183–0.286]; p < .0001). The
durability of PFS noted in our trial is consistent with
previously published observations in randomized trials
evaluating single-agent ibrutinib in comparable
patient populations and in patients with previously
untreated CLL [9,19].
Unlike the interim analysis of HELIOS, the 3-year
analysis showed an improved median OS with ibrutinib plus BR (HR 0.652 [95% CI 0.454–0.935]; p ¼ .019).
In this final analysis, the long median PFS with ibrutinib plus BR translated into an OS benefit (HR 0.611
[95% CI 0.455–0.822]; p ¼ .0010), despite 63.3% of
patients crossing over from the placebo plus BR arm
to ibrutinib treatment. The RESONATE study also
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Figure 4. Prevalence of any grade TEAEs over time in the ibrutinib arm for (A) TEAEs of clinical interest and (B) TEAEs occurring
in 30% of patients in the final analysis. aMajor hemorrhage TEAEs included serious/grade 3 hemorrhage and any grade central
nervous system hemorrhage.

demonstrated an OS benefit with ibrutinib versus ofatumumab for R/R CLL/SLL (HR 0.639 [95% CI
0.418–0.975]) [10]. Additionally, median PFS2 was substantially longer for patients in the ibrutinib plus BR
arm despite crossover, further supporting the benefit
of earlier treatment with ibrutinib. Among the subgroups of patients who received subsequent therapies,
those who received ibrutinib as next treatment after
placebo plus BR had the longest time to next progression or death. For those who received other antineoplastic subsequent therapies, there was no meaningful
difference in time to next progression or death for
those who previously received ibrutinib plus BR or placebo plus BR, indicating that prior ibrutinib treatment
did not impact efficacy of subsequent therapy. The

small individual numbers of patients treated with specific alternative therapies do not allow a recommendation of a particular treatment for patients relapsing
after ibrutinib-based therapy, although responses,
including complete remissions, were observed in
patients treated with venetoclax regimens after ibrutinib plus BR.
Responses to ibrutinib plus BR in the HELIOS study
were durable and deepened over time. The final analysis also showed a significant increase in CR/CRi rate
(40.8%) compared with the interim analysis (21%),
reflecting the ongoing benefit of continuous treatment with ibrutinib. The rate of undetectable MRD in
peripheral blood and bone marrow plateaued and
testing was discontinued shortly after the 3-year
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analysis, but 29% of patients had undetectable MRD
at the last analysis. The PFS curve did not show a plateau at the final analysis, with a duration of follow-up
very close to the median PFS, despite deepening
responses over time.
Safety findings were consistent with known safety
profiles of ibrutinib and BR in patients with CLL
[9,20–22], and there were no unexpected findings at
the latest follow-up analysis compared with the 3-year
analysis. Consistent with prior analyses [15,16], this
extended 5-year follow-up analysis demonstrates the
manageable safety profile of ibrutinib. From the
interim results to final analysis, the prevalence of
TEAEs including serious TEAEs trended lower over
time with ibrutinib. However, it is notable that the
number of patients on treatment also decreased,
partly because of discontinuations due to AEs. Overall,
the prevalence of hypertension, atrial fibrillation, and
major hemorrhage events decreased over time
throughout the study. Rates of infections and infestations, including pneumonia, also declined over time
and the incidence of serious opportunistic infections,
e.g. Aspergillus, Cryptococcus, and Pneumocystis,
was low.
Our study is limited as it did not evaluate whether
ibrutinib plus BR is more beneficial than single-agent
ibrutinib in a relapsed setting. Nonetheless, an indirect
comparison of the RESONATE and HELIOS trials, after
adjusting for known confounding variables, has previously been published [23]. That analysis comparing
single-agent ibrutinib with ibrutinib plus BR suggested
that single-agent ibrutinib was superior for PFS and
OS. The analysis also suggested that an induction
period with BR did not improve outcomes, however,
only short-term follow-up of both trials was available
at the time of the published comparison, preventing
firm conclusions. Similarly, in a recently published
randomized trial in 208 patients with CLL (most [181]
with R/R CLL), ibrutinib plus rituximab did not improve
PFS versus single-agent ibrutinib despite faster remissions and lower levels of residual disease in patients
receiving the combination. A recent study (Alliance
A041202) in patients with previously untreated CLL
also demonstrated no additional benefit of adding rituximab to ibrutinib for PFS, in the first-line setting
[19]. However, due to differences in patient populations, study design, and treatment regimens, it is difficult to make indirect cross-trial comparisons.
Lack of resistance testing is another limitation of
this trial, as only a few genomic biomarker samples
were available. However, CLL remains an incurable disease and eventually the disease progresses further in
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most patients with R/R CLL despite the therapy advances of previous years. Therefore, it is important to
assess adverse biologic features and resistance mechanisms leading to treatment resistance in current and
future CLL studies to establish predictive biomarkers,
customize therapy, and enhance therapy outcomes.
In conclusion, with an extended median follow-up
of 63.7 months, this final analysis confirms the longterm safety and efficacy of ibrutinib plus BR in
patients with R/R CLL/SLL. In this patient population
with a median of 2.0 prior lines of therapy, median
PFS in the ibrutinib plus BR arm was 5.4 years and the
OS rate at 5 years was 75.7%. Long-term safety findings for the ibrutinib plus BR arm were also consistent
with the known safety profiles of ibrutinib and BR and
support a positive benefit/risk profile for continuous
ibrutinib treatment.

Acknowledgments
Writing assistance was provided by Sally Hassan, PhD, CMPP
of Parexel and funded by Janssen Global Services, LLC. The
authors would like to thank patients who participated in this
trial, their families, investigators, study coordinators, study
teams, and nurses.

Disclosure statement
GAMF had a consultant/advisory role with AbbVie and
Janssen. FD had a consultant/advisory role with AbbVie and
Roche, received research funding from AbbVie and Janssen,
honoraria from Amgen and Janssen, and was on a speakers’
bureau for Amgen and Janssen. RSS had a consultant/advisory role with AstraZeneca and Janssen and was on a speakers’ bureau for Janssen. AJ had a consultant/advisory role
with Gilead Sciences, Janssen, Roche, and Sanofi Genzyme,
was on a speakers’ bureau for AbbVie, Amgen, and Novartis,
and received other financial/material support from Celgene.
JM received research funding from Janssen-Cilag. NLB had a
consultant/advisory role with ADC Therapeutics, Acerta, and
BTG Therapeutics and received research funding from
Autolus, Bristol Meyers Squibb, Celgene, Forty Seven,
Genentech, Immune Design, Janssen, Kite Pharma, Merck,
Millennium, Pharmacyclics, and Seattle Genetics. M-SD had a
consultant/advisory role with AbbVie and Janssen and
received honoraria from AbbVie and Janssen. JL had a consultant/advisory role with AbbVie, AstraZeneca, Gilead
Sciences, Janssen, and Roche. SR had a consultant/advisory
role with AstraZeneca, BeiGene, Celgene, Celltrion, Gilead
Sciences, Janssen, Kite Pharma, Roche, and Sunesis
Pharmaceuticals, received research funding from Janssen
and Pharmacyclics, and was on a speakers’ bureau for
Janssen and Roche. MAP had a consultant/advisory role with
AstraZeneca and Janssen, and was on a speakers’ bureau for
AbbVie, Janssen, Novartis, and Roche. AG had a consultant/
advisory role with and received honoraria from Acerta,
Celgene, Gilead Sciences/Kite Pharma, and Janssen, received
research funding from Acerta, AstraZeneca, Bayer, CALBG,

3196

G. A. M. FRASER ET AL.

Celgene, Genentech, Hoffman-La Roche, Janssen, Kite
Pharma, MD Anderson, MorphoSys AG, Pharmacyclics, and
the University of Nebraska, and is on the board and a shareholder of COTA. AM had a consultant role with and received
research funding from AbbVie, Acerta, Janssen, Loxo
Oncology,
Pharmacyclics,
Genentech,
Sunesis
Pharmaceuticals, and TG Therapeutics, received research
funding from DTRM and Regeneron, and was on the Data
and Safety Monitoring Board for Celgene and TG
Therapeutics. MH had a consultant/advisory role with
AbbVie, Celgene, Gilead Sciences, Janssen, Mundipharma,
Pharmacyclics, and Roche, received research funding from
AbbVie, Celgene, Gilead Sciences, Janssen, Mundipharma,
Pharmacyclics, and Roche, and was on a speakers’ bureau
for AbbVie, Celgene, Gilead Sciences, Janssen, Mundipharma,
Pharmacyclics, and Roche. MS, AC, KN, SB, and AH hold J&J
stock and are employed by Janssen R&D. SB also holds
AbbVie stock. MT and SS are also employees of Janssen. NS
holds J&J stock and is employed by Janssen-Cilag. PC had a
consultant/advisory role with AbbVie, Acerta Pharma,
AstraZeneca, Janssen-Cilag, and Novartis, was on a speakers’
bureau for AbbVie, F. Hoffmann-LaRoche, and Janssen-Cilag,
and received other financial/material support from AbbVie,
Acerta Pharma, AstraZenca, F. Hoffmann-LaRoche, Gilead
Sciences, GlaxoSmithKline, Janssen-Cilag, and Novartis. AC-K,
SG, AA, and OS have no conflicts of interest to disclose.

ORCID

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

Nancy L. Bartlett
http://orcid.org/0000-0001-8470-394X
Simon Rule
http://orcid.org/0000-0001-8937-6351

Data availability
The data sharing policy of Janssen Pharmaceutical
Companies of Johnson & Johnson is available at https://
www.janssen.com/clinical-trials/transparency. As noted on
this site, requests for study data access can be submitted
through Yale Open Data Access (YODA) Project site at
http://yoda.yale.edu.

[14]

[15]

References
[1]

[2]
[3]

[4]

[5]

IMBRUVICAV (ibrutinib) [prescribing information].
Sunnyvale, CA: Pharmacyclics LLC; Janssen Biotech,
Inc.: Horsham, PA; 2019.
IMBRUVICA (ibrutinib) [summary of product characteristics]. Belgium: Janssen Pharmaceutica NV; 2019.
Gayko U, Fung M, Clow F, et al. Development of the
Bruton’s tyrosine kinase inhibitor ibrutinib for B cell
malignancies. Ann N Y Acad Sci. 2015;1358:82–94.
Byrd JC, Jones JJ, Woyach JA, et al. Entering the era
of targeted therapy for chronic lymphocytic leukemia:
impact on the practicing clinician. J Clin Oncol. 2014;
32(27):3039–3047.
Dias AL, Jain D. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton’s
tyrosine kinase inhibition. Cardiovasc Hematol Agents
Med Chem. 2014;11(4):265–271.
R

[16]

[17]

[18]

National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology. Chronic
Lymphocytic
Leukemia/Small
Lymphocytic
Lymphoma. NCCN Evidence BlocksTM Version 1.2020;
[cited 2019 Sep 18]. Available from: https://www.nccn.
org/professionals/physician_gls/pdf/cll_blocks.pdf.
Molica S. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia:
new data presented at ASCO 2017. BMC Med. 2017;
15(1):156.
Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus
ofatumumab in previously treated chronic lymphoid
leukemia. N Engl J Med. 2014;371(3):213–223.
Byrd JC, Hillmen P, O’Brien S, et al. Long-term followup of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
Munir T, Brown JR, O’Brien S, et al. Final analysis from
RESONATE: up to six years of follow-up on ibrutinib
in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J
Hematol. 2019;94(12):1353–1363.
Eichhorst B, Dreyling M, Robak T, et al. Chronic
lymphocytic leukemia: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2011;22(Suppl 6):vi50–vi54.
Gordon MJ, Lewis LD, Brown JR, et al. Bendamustine
hydrochloride in patients with B-cell malignancies
who have comorbidities – is there an optimal dose?
Expert Rev Hematol. 2017;10(8):707–718.
Fischer K, Cramer P, Busch R, et al. Bendamustine
combined with rituximab in patients with relapsed
and/or refractory chronic lymphocytic leukemia: a
multicenter phase II trial of the German Chronic
Lymphocytic Leukemia Study Group. J Clin Oncol.
2011;29(26):3559–3566.
Brown JR, Barrientos JC, Barr PM, et al. The Bruton
tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915–2922.
Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib
combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for
previously treated chronic lymphocytic leukaemia or
small lymphocytic lymphoma (HELIOS): a randomised,
double-blind, phase 3 study. Lancet Oncol. 2016;17(2):
200–211.
Fraser G, Cramer P, Demirkan F, et al. Updated results
from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic
leukemia/small
lymphocytic
lymphoma.
Leukemia. 2019;33(4):969–980.
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for
the diagnosis and treatment of chronic lymphocytic
leukemia: a report from the International Workshop
on Chronic Lymphocytic Leukemia updating the
National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
van Dongen JJ, Lhermitte L, Bottcher S, et al.
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia.
2012;26(9):1908–1975.

FINAL 5-YEAR HELIOS STUDY FINDINGS

[19]

[20]

[21]

[22]

Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib
regimens versus chemoimmunotherapy in older
patients with untreated CLL. N Engl J Med. 2018;
379(26):2517–2528.
Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated
patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK
with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab

[23]

3197

versus fludarabine, cyclophosphamide, and rituximab
in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol.
2016;17(7):928–942.
Hillmen P, Fraser G, Jones J, et al. Comparing singleagent ibrutinib, bendamustine plus rituximab (BR)
and ibrutinib plus BR in patients with previously
treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an indirect comparison of
the RESONATE and HELIOS trials [abstract]. 57th ASH
Annual Meeting; 5–8 December 2015; Orlando, FL;
Abstract 2944.

